Neil Goldsmith

Neil is a serial biotechnology entrepreneur with 35 years’ experience of the life science sector, having built companies from the ground up in multiple sectors (industrial biotech, therapeutics, lab instrumentation, sensors & diagnostics, services) and countries (UK, Sweden, Denmark, Switzerland, USA, India).

From 2004 to 2017 Neil was founder and CEO of Evolva SA, a pioneering synthetic biology company that scaled multiple products to market, and that went public in Switzerland in 2009. Before that Neil founded, or played a key early role in, amongst others, TopoTarget (cancer therapeutics, IPO Copenhagen), Biotage (microwave chemistry, IPO Stockholm), GX Biosystems (suicide systems for GM microbes), PNA Diagnostics (DNA diagnostics, trade sale to Boehringer Mannheim, now Roche), BIAcore (biosensors, IPO NASDAQ) & Scientific Generics (technology consultancy, IPO LSE). Neil has a 1st class honours degree in Zoology from Oxford University.